BIIB122 for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Apr 2022: Trial started, NCT05348785
  2. 27 Apr 2022: Trial registered, NCT05348785

The trials

NCT05348785: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

State
Completed
Phase
Phase 2
People
650 taking part
Started
19 Apr 2022
Primary completion
9 Mar 2026
Arms
BIIB122 225 mg
Results
None posted
  1. 19 Apr 2022: Trial started
  2. 27 Apr 2022: Trial registered
  3. 9 Mar 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.